Sudeep Pharma IPO Subscribed over 5.11x on Day 2

Sudeep Pharma IPO subscription started on November 21, 2025, and the IPO will close on November 25, 2025, as per the schedule. The price band is set at ₹563 to ₹593 per share with a face value of ₹1 each.

Sudeep Pharma IPO Subscription Status

Sudeep Pharma IPO subscribed over 5.11x on its second day till 5.00 PM on November 24, 2025.

Sudeep Pharma IPO subscription QIB investors’ portion is 0.13 times, while NII subscribed 12.01 times, and RII investors subscribed 4.99 times.
The company has received bids for 5,39,80,500 shares against 1,05,64,927 shares on offer on the second day of subscription.
Sudeep Pharma IPO subscribed over 5.11x on day 2.
Sudeep Pharma IPO subscribed over 1.43x on day 1.

About Sudeep Pharma Company

Sudeep Pharma Limited, founded in 1989, is one of the leading manufacturers of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries. They aim to support the global healthcare ecosystem by serving their product to over 100 countries and supplying more than 200 products. To support innovation in their work, they use their own in-house technologies for encapsulation, spray drying, granulation, trituration, liposomal preparations, and mixing.

Their business is basically structured into 2 verticals: 1) Pharmaceutical, food, and nutrition, which includes key mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, and copper, and 2) Specialty Ingredients includes micronutrient premixes, encapsulated ingredients, granulated minerals, and triturated blends. Moreover, Sudeep Pharma runs six manufacturing facilities with a total production capacity of 50,000 MT.

Sudeep Pharma IPO GMP:

Sudeep Pharma’s IPO GMP was ₹115 as of Monday, November 24, 2025. That indicates the IPO is trading at ₹708 with a ₹115 premium in the grey market against the issue price of ₹593.

Vijay Prajapati

An experienced stock market professional with expertise in IPO research, market insights, and equity strategies. With a strong background in research and capital markets, he delivers comprehensive coverage on upcoming IPOs, subscription patterns, grey market premium (GMP), and post-listing performance, along with detailed reviews, recommendations, and technical analysis.

Add IPOWatch to your Google News feed.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.